|Bid||6.83 x 0|
|Ask||6.84 x 0|
|Day's Range||6.72 - 6.95|
|52 Week Range||4.11 - 11.30|
|Beta (3Y Monthly)||3.97|
|PE Ratio (TTM)||30.99|
|Earnings Date||Jul 27, 2017 - Jul 28, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.84|
Organigram Holdings Inc. (OGI) (TSX VENTURE: OGI), the parent company of Organigram Inc. (the “Company” or “Organigram”), a leading licensed producer of cannabis, is pleased to announce that it has received final approval for the listing of its common shares on the Toronto Stock Exchange (“TSX”).
If you don't own these up-and-coming small companies in your investment portfolio yet, you could be missing out on a big opportunity for market-beating returns.
TSX-V: OGI) the parent company of Organigram Inc. (collectively the “Company” or “Organigram”), a leading licensed producer of cannabis, is pleased to announce that it has entered into an advance payment and purchase agreement (the “Payment Agreement”) with 703454 N.B. Inc. (carrying on business as 1812 Hemp) (“1812 Hemp”) under which the Company will pre-fund hemp purchases to receive access to as much as 60,000 kilograms of dried hemp flower to be harvested in calendar 2019 for extraction into cannabidiol (“CBD”) isolate.
OrganiGram Holdings Inc. (TSXV:OGI)(NASDAQ:OGI) and HEXO Corp. (TSX:HEXO)(NYSE:HEXO) are shaping up as the best ways to play the legalization of cannabis edibles.
Curaleaf is buying expansion with its $875 acquisition of Grassroots. Meanwhile, OrganiGram reported Q3 results, and Aurora Cannabis had a good news/bad news week.
Aurora Cannabis Inc (TSX:ACB)(NYSE:ACB) has achieved significant sales growth recently, but that doesn't mean that the stock is the best option for cannabis investors today.
OrganiGram remains on track to complete its Moncton campus by year's end, and is eagerly awaiting the launch of derivative cannabis products in December.